MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations. (Q48824616)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

David T. W. Jones

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Magnus L Bäcklund

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Shani Mulholland

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Danita M Pearson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Deborah S Malley

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Caroline M Smith

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Jamie M J Weaver

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Sylvia Kocialkowski

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

V Peter Collins

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Koichi Ichimura

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

language of work or name

English

0 references

publication date

11 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Cancer

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

131

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

1104-1113

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22020830%20AND%20SRC:MED&resulttype=core&format=json

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

15 January 2020

cites work

1 reference

Molecular diagnostics of gliomas: state of the art.

21 January 2018

1 reference

Molecular diagnostics of gliomas: the clinical perspective

21 January 2018

1 reference

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

21 January 2018

1 reference

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

21 January 2018

1 reference

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

21 January 2018

1 reference

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis

21 January 2018

1 reference

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma

21 January 2018

1 reference

Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.

21 January 2018

1 reference

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

21 January 2018

1 reference

BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas.

21 January 2018

1 reference

Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses

21 January 2018

1 reference

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

21 January 2018

1 reference

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

MGMT: its role in cancer aetiology and cancer therapeutics

21 January 2018

1 reference

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

21 January 2018

1 reference

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

21 January 2018

1 reference

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.

21 January 2018

1 reference

Real-time quantitative polymerase chain reaction (qPCR) analysis with fluorescence resonance energy transfer (FRET) probes reveals differential expression of the four ERBB4 juxtamembrane region variants between medulloblastoma and pilocytic astrocyt

21 January 2018

1 reference

Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age.

21 January 2018

1 reference

Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts.

21 January 2018

1 reference

Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene

21 January 2018

1 reference

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

21 January 2018

1 reference

Adult grade II diffuse astrocytomas are genetically distinct from and more aggressive than their paediatric counterparts.

21 January 2018

1 reference

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

21 January 2018

1 reference

Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods

21 January 2018

1 reference

Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.

21 January 2018

1 reference

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

Active DNA demethylation: many roads lead to Rome.

21 January 2018

1 reference

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

21 January 2018

1 reference

Endogenous DNA damage in humans: a review of quantitative data

21 January 2018

1 reference

Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer

21 January 2018

1 reference

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene

21 January 2018

1 reference